Page last updated: 2024-11-05

2,4-thiazolidinedione and Parkinson Disease, Secondary

2,4-thiazolidinedione has been researched along with Parkinson Disease, Secondary in 1 studies

thiazolidine-2,4-dione: structure in first source
1,3-thiazolidine-2,4-dione : A thiazolidenedione carrying oxo substituents at positions 2 and 4.

Parkinson Disease, Secondary: Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Connolly, JG1
Bykov, K1
Gagne, JJ1

Other Studies

1 other study available for 2,4-thiazolidinedione and Parkinson Disease, Secondary

ArticleYear
Thiazolidinediones and Parkinson Disease: A Cohort Study.
    American journal of epidemiology, 2015, Dec-01, Volume: 182, Issue:11

    Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Parkinso

2015